Onkos Molecular Diagnostics Information

Onkos is a CAP-Accredited company provider of proprietary gene expression-based diagnostic tests that is focused on providing answers to diagnostic uncertainties in Oncology by avoiding unnecessary procedures. We guide informed clinical decisions to enable not only the best patient management available but also healthcare providers' efficiencies and savings. Our Gene Expression Profiling platform merges cutting-edge technologies of molecular biology and artificial intelligence tools to create molecular classifiers that are translated into actionable results to unlock the best care for cancer patients. Our current portfolio is composed of the two first gene expression-based tests developed and applied on clinical routine in the southern hemisphere: a. mir-THYpe®, which is a microRNA-based and DNA-based diagnostic and prognostic molecular classifier for thyroid nodules with indeterminate cytology. To date, we are driving a revolution reducing up to 75% of unnecessary thyroid surgeries, with robust and high level scientific evidence. b. TOT- Tumor Origin Test, which is a mRNA-based molecular classifier for Metastatic Cancers with Unknown Primary site. We are providing data that can help physicians with treatment decisions resulting in the patient's best care. We have operations in Spain and Brazil, but if you live in the Earth, we can easily test your thyroid! Science, Evidence & True Impact.